Your browser doesn't support javascript.
loading
Bismuth quadruple three-in-one single capsule three times a day increases effectiveness compared with the usual four times a day schedule: results from the European Registry on Helicobacter pylori Management (Hp-EuReg).
Pérez-Aisa, Ángeles; Nyssen, Olga P; Keco-Huerga, Alma; Rodrigo, Luís; Lucendo, Alfredo J; Gomez-Rodriguez, Blas J; Ortuño, Juan; Perona, Mónica; Huguet, José María; Núñez, Oscar; Fernandez-Salazar, Luis; Barrio, Jesus; Lanas, Angel; Iyo, Eduardo; Romero, Pilar Mata; Fernández-Bermejo, Miguel; Gomez, Barbara; Garre, Ana; Gomez-Camarero, Judith; Lamuela, Luis Javier; Campillo, Ana; de la Peña-Negro, Luisa; Dominguez Cajal, Manuel; Bujanda, Luis; Burgos-Santamaría, Diego; Bermejo, Fernando; González-Carrera, Víctor; Pajares, Ramón; Notari, Pedro Almela; Tejedor-Tejada, Javier; Planella, Montserrat; Jiménez, Itxaso; Lázaro, Yolanda Arguedas; Cuadrado-Lavín, Antonio; Pérez-Martínez, Isabel; Amorena, Edurne; Gonzalez-Santiago, Jesús M; Angueira, Teresa; Flores, Virginia; Martínez-Domínguez, Samuel J; Pabón-Carrasco, Manuel; Velayos, Benito; Algaba, Alicia; Ramírez, Consuelo; Almajano, Enrique Alfaro; Castro-Fernandez, Manuel; Alcaide, Noelia; Sanz Segura, Patricia; Cano-Català, Anna; García-Morales, Natalia.
Afiliação
  • Pérez-Aisa Á; Department of Gastroenterology, Hospital Costal del Sol, Marbella, Spain.
  • Nyssen OP; Redes de Investigación Cooperativa orientada a Resultados en Salud (RICORS), Marbella, Spain.
  • Keco-Huerga A; Department of Gastroenterology, Hospital Universitario de La Princesa, Instituto de Investigación Sanitaria Princesa, Universidad Autónoma de Madrid, Madrid, Spain.
  • Rodrigo L; Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas, Madrid, Spain.
  • Lucendo AJ; Department of Gastroenterology, Hospital de Valme, Sevilla, Spain.
  • Gomez-Rodriguez BJ; Gastroenterology Service, Hospital Universitario Central de Asturias, Oviedo, Spain.
  • Ortuño J; Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas, Madrid, Spain.
  • Perona M; Department of Gastroenterology, Hospital General Tomelloso, Tomelloso, Spain.
  • Huguet JM; Instituto de Investigación Sanitaria de Castilla-La Mancha (IDISCAM), Madrid, Spain.
  • Núñez O; Instituto de Investigación Sanitaria Princesa (IIS-Princesa), UniversidadAutónoma de Madrid (UAM), Madrid, Spain.
  • Fernandez-Salazar L; Department of Gastroenterology, Hospital Virgen de la Macarena, Seville, Spain.
  • Barrio J; Department of Gastroenterology, Hospital Universitari i Politècnic La Fe, Valencia, Spain.
  • Lanas A; Department of Gastroenterology, Hospital Quiron Marbella, Marbella, Spain.
  • Iyo E; Gastroenterology Unit, Consorci Hospital General Universitari de Valencia, Valencia, Spain.
  • Romero PM; Department of Digestive Diseases, Hospital Universitario Sanitas La Moraleja, Madrid, Spain.
  • Fernández-Bermejo M; Gastroenterologia, Hospital Clínico Universitario Valladolid, Gerencia Regional de Salud (SACYL), Valladolid, Spain.
  • Gomez B; Facultad de Medicina, Universidad de Valladolid, Valladolid, Spain.
  • Garre A; Department of Gastroenterology, Hospital Rio Hortega, Valladolid, Spain.
  • Gomez-Camarero J; Instituto de Investigación Sanitària de Aragón (IIS Aragorn), Zaragoza, Spain.
  • Lamuela LJ; Facultad de Medicina. Universidad de Zaragoza, Zaragoza, Spain.
  • Campillo A; Department of Gastroenterology, Hospital Clínico Universitario Lozano Blesa, Zaragoza, Spain.
  • de la Peña-Negro L; Digestive Service, Hospital Comarcal de Inca, Inca, Mallorca, Spain.
  • Dominguez Cajal M; Department of Gastroenterology, Hospital Universitario de Caceres, Cáceres, Spain.
  • Bujanda L; Digestive Service, Clínica San Francisco, Cáceres, Spain.
  • Burgos-Santamaría D; Department of Gastroenterology, Hospital de Mataró, Mataro, Spain.
  • Bermejo F; Department of Gastroenterology, Hospital Universitario de La Princesa, Instituto de Investigación Sanitaria Princesa, Universidad Autónoma de Madrid, Madrid, Spain.
  • González-Carrera V; Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas, Madrid, Spain.
  • Pajares R; Department of Gastroenterology, Hospital Universitario de Burgos, Burgos, Spain.
  • Notari PA; Instituto de Investigación Sanitària de Aragón (IIS Aragorn), Zaragoza, Spain.
  • Tejedor-Tejada J; Department of Gastroenterology, Hospital Universitario Miguel Servet, Zaragoza, Spain.
  • Planella M; Department of Gastroenterology, Hospital Reina Sofía, Tudela, Spain.
  • Jiménez I; Digestive Diseases Department, Hospital of Viladecans, Viladecans, Spain.
  • Lázaro YA; Department of Gastroenterology, Hospital General San Jorge, Huesca, Spain.
  • Cuadrado-Lavín A; Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas, Madrid, Spain.
  • Pérez-Martínez I; Department of Gastroenterology, Hospital Donostia, Instituto Biodonostia, Universidad del País Vasco (UPV/EHU), San Sebastian, Spain.
  • Amorena E; Department of Gastroenterology and Hepatology, Hospital Universitario Ramon y Cajal, Madrid, Spain.
  • Gonzalez-Santiago JM; Department of Gastroenterology, Hospital Universitario de Fuenlabrada, Madrid, Spain.
  • Angueira T; Instituto de Investigación Sanitaria La Paz, Madrid, Spain.
  • Flores V; Department of Gastroenterology, Hospital General de Almansa, Almansa, Albacete, Spain.
  • Martínez-Domínguez SJ; Department of Gastroenterology, Hospital Universitario Infanta Sofía, San Sebastian de los Reyes, Madrid, Spain.
  • Pabón-Carrasco M; Medicine Department, Universidad Europea de Madrid SLU, Madrid, Spain.
  • Velayos B; Digestive Service, Hospital General Universitari de Castelló, Castellon de la Plana, Spain.
  • Algaba A; Department of Gastroenterology, Hospital Universitario de Cabueñes, Gijon, Spain.
  • Ramírez C; Department of Gastroenterology, Hospital Universitari Arnau de Vilanova, Lleida, Spain.
  • Almajano EA; Department of Gastroenterology, Hospital Universitario de Galdakao-Usansolo, Galdakao, Spain.
  • Castro-Fernandez M; Department of Gastroenterology, Hospital Royo Villanova, Zaragoza, Spain.
  • Alcaide N; Digestive Service, Hospital Universitario Marqués de Valdecilla, Santander, Spain.
  • Sanz Segura P; Department of Gastroenterology, Hospital Universitario Central de Asturias, Oviedo, Spain.
  • Cano-Català A; Department of Gastroenterology, Complejo Hospitalario de Navarra, Pamplona, Spain.
  • García-Morales N; Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas, Madrid, Spain.
Gut ; 72(11): 2031-2038, 2023 11.
Article em En | MEDLINE | ID: mdl-37468228
ABSTRACT

BACKGROUND:

The recommended schedule for single capsule bismuth quadruple therapy (scBQT, Pylera) includes a proton pump inhibitor (PPI) two times a day and three scBQT capsules four times a day. Four times a day treatments are inconvenient and reduce adherence. In contrast, adherence improves with three times a day schedules. In clinical practice, many gastroenterologists use four capsule scBQT three times a day. However, the effectiveness and safety of this latter approach remain uncertain.

AIM:

To assess the effectiveness and safety of scBQT administered three times a day in the patients included in the European Registry on Helicobacter pylori Management (Hp-EuReg).

METHODS:

All Spanish adult patients registered in the Asociación Española de Gastroenterología Research Electronic Data Capture (REDCap) database from June 2013 to March 2021 receiving 10-day scBQT were analysed. Modified intention-to-treat effectiveness, adherence and the safety of scBQT given three times a day were calculated and compared with the four times a day schedule. A multivariate analysis was performed to determine independent factors predicting cure of the infection.

RESULTS:

Of the 3712 cases, 2516 (68%) were four times a day and 1196 (32%) three times a day. Mean age was 51 years, 63% were women and 15% had a peptic ulcer. The three times a day schedule showed significantly better overall cure rates than four times a day (1047/1112, 94%; 95% CI 92.7 to 95.6 vs 2207/2423, 91%; 95% CI 89.9 to 92.2, respectively, p=0.002). Adherence and safety data were similar for both regimens. In the multivariate analysis, three times a day dosage, first-line therapy, use of standard or high-dose PPIs and adherence over 90% were significantly associated with cure of the infection.

CONCLUSIONS:

ScBQT prescribed three times a day was more effective than the traditional four times a day schedule. No differences were observed in treatment adherence or safety.
Assuntos
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Helicobacter pylori / Infecções por Helicobacter Tipo de estudo: Prognostic_studies Limite: Adult / Female / Humans / Male / Middle aged Idioma: En Revista: Gut Ano de publicação: 2023 Tipo de documento: Article País de afiliação: Espanha

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Helicobacter pylori / Infecções por Helicobacter Tipo de estudo: Prognostic_studies Limite: Adult / Female / Humans / Male / Middle aged Idioma: En Revista: Gut Ano de publicação: 2023 Tipo de documento: Article País de afiliação: Espanha
...